Close Menu

Taking on H5N1

NIH announced that a vaccine for H5N1 avian flu designed by scientists at the National Institute of Allergy and Infectious Diseases has entered clinical trials. The DNA-based vaccine is the first to start human trials, according to NIH. If all goes well with this vaccine, it could help pave the way for development of other DNA-based, rather than virus-based, vaccines.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.